Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Bruck syndrome 2 variant lacking congenital contractures and involving a novel compound heterozygous PLOD2 mutation.

Mumm S, Gottesman GS, Wenkert D, Campeau PM, Nenninger A, Huskey M, Bijanki VN, Veis DJ, Barnes AM, Marini JC, Stolina M, Zhang F, McAlister WH, Whyte MP.

Bone. 2019 Aug 28:115047. doi: 10.1016/j.bone.2019.115047. [Epub ahead of print]

PMID:
31472299
2.

Clinically Relevant Doses of Sclerostin Antibody Do Not Induce Osteonecrosis of the Jaw (ONJ) in Rats with Experimental Periodontitis.

Hadaya D, Gkouveris I, Soundia A, Bezouglaia O, Boyce RW, Stolina M, Dwyer D, Dry SM, Pirih FQ, Aghaloo TL, Tetradis S.

J Bone Miner Res. 2019 Jan;34(1):171-181. doi: 10.1002/jbmr.3581. Epub 2018 Sep 24.

PMID:
30184271
3.

Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss.

Liu M, Kurimoto P, Zhang J, Niu QT, Stolina M, Dechow PC, Feng JQ, Hesterman J, Silva MD, Ominsky MS, Richards WG, Ke H, Kostenuik PJ.

J Dent Res. 2018 Aug;97(9):1031-1038. doi: 10.1177/0022034518766874. Epub 2018 Apr 4.

PMID:
29617179
4.

Gnathodiaphyseal dysplasia: Severe atypical presentation with novel heterozygous mutation of the anoctamin gene (ANO5).

Otaify GA, Whyte MP, Gottesman GS, McAlister WH, Eric Gordon J, Hollander A, Andrews MV, El-Mofty SK, Chen WS, Veis DV, Stolina M, Woo AS, Katsonis P, Lichtarge O, Zhang F, Shinawi M.

Bone. 2018 Feb;107:161-171. doi: 10.1016/j.bone.2017.11.012. Epub 2017 Nov 21.

5.

Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.

Yu L, Tomlinson JE, Alexander ST, Hensley K, Han CY, Dwyer D, Stolina M, Dean C Jr, Goodman WG, Richards WG, Li X.

Calcif Tissue Int. 2017 Dec;101(6):641-653. doi: 10.1007/s00223-017-0319-7. Epub 2017 Oct 16.

6.

Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.

Li X, Yu L, Asuncion F, Grisanti M, Alexander S, Hensley K, Han CY, Niu QT, Dwyer D, Villasenor K, Stolina M, Dean C Jr, Ominsky MS, Ke HZ, Tomlinson JE, Richards WG.

Bone. 2017 Dec;105:163-172. doi: 10.1016/j.bone.2017.08.026. Epub 2017 Sep 1.

7.

Sclerostin antibody inhibits skeletal deterioration in mice exposed to partial weight-bearing.

Spatz JM, Ellman R, Cloutier AM, Louis L, van Vliet M, Dwyer D, Stolina M, Ke HZ, Bouxsein ML.

Life Sci Space Res (Amst). 2017 Feb;12:32-38. doi: 10.1016/j.lssr.2017.01.001. Epub 2017 Jan 12.

PMID:
28212706
8.

FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists.

Li X, Stanislaus S, Asuncion F, Niu QT, Chinookoswong N, Villasenor K, Wang J, Wong P, Boyce R, Dwyer D, Han CY, Chen MM, Liu B, Stolina M, Ke HZ, Ominsky MS, Véniant MM, Xu J.

J Bone Miner Res. 2017 Apr;32(4):834-845. doi: 10.1002/jbmr.2936. Epub 2016 Sep 9.

9.

A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair.

Florio M, Gunasekaran K, Stolina M, Li X, Liu L, Tipton B, Salimi-Moosavi H, Asuncion FJ, Li C, Sun B, Tan HL, Zhang L, Han CY, Case R, Duguay AN, Grisanti M, Stevens J, Pretorius JK, Pacheco E, Jones H, Chen Q, Soriano BD, Wen J, Heron B, Jacobsen FW, Brisan E, Richards WG, Ke HZ, Ominsky MS.

Nat Commun. 2016 May 27;7:11505. doi: 10.1038/ncomms11505.

10.

Idiopathic Acquired Osteosclerosis in a Middle-Aged Woman With Systemic Lupus Erythematosus.

Guañabens N, Mumm S, Gifre L, Ruiz-Gaspà S, Demertzis JL, Stolina M, Novack DV, Whyte MP.

J Bone Miner Res. 2016 Sep;31(9):1774-82. doi: 10.1002/jbmr.2842. Epub 2016 May 9.

11.

Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.

Ominsky MS, Brown DL, Van G, Cordover D, Pacheco E, Frazier E, Cherepow L, Higgins-Garn M, Aguirre JI, Wronski TJ, Stolina M, Zhou L, Pyrah I, Boyce RW.

Bone. 2015 Dec;81:380-391. doi: 10.1016/j.bone.2015.08.007. Epub 2015 Aug 8.

12.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.

PMID:
26059012
13.

Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.

Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ.

Endocrinology. 2014 Dec;155(12):4785-97. doi: 10.1210/en.2013-1905. Epub 2014 Sep 26.

PMID:
25259718
14.

Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.

Stolina M, Dwyer D, Niu QT, Villasenor KS, Kurimoto P, Grisanti M, Han CY, Liu M, Li X, Ominsky MS, Ke HZ, Kostenuik PJ.

Bone. 2014 Oct;67:305-13. doi: 10.1016/j.bone.2014.07.031. Epub 2014 Aug 2.

PMID:
25093263
15.

Rapid skeletal turnover in a radiographic mimic of osteopetrosis.

Whyte MP, Madson KL, Mumm S, McAlister WH, Novack DV, Blair JC, Helliwell TR, Stolina M, Abernethy LJ, Shaw NJ.

J Bone Miner Res. 2014 Dec;29(12):2601-9. doi: 10.1002/jbmr.2289.

16.

Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model.

Alaee F, Virk MS, Tang H, Sugiyama O, Adams DJ, Stolina M, Dwyer D, Ominsky MS, Ke HZ, Lieberman JR.

J Orthop Res. 2014 Feb;32(2):197-203. Epub 2013 Nov 8.

PMID:
24600701
17.

Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice.

Rinotas V, Niti A, Dacquin R, Bonnet N, Stolina M, Han CY, Kostenuik P, Jurdic P, Ferrari S, Douni E.

J Bone Miner Res. 2014;29(5):1158-69. doi: 10.1002/jbmr.2112.

18.

Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis.

Chen XX, Baum W, Dwyer D, Stock M, Schwabe K, Ke HZ, Stolina M, Schett G, Bozec A.

Ann Rheum Dis. 2013 Oct;72(10):1732-6. doi: 10.1136/annrheumdis-2013-203345. Epub 2013 May 10.

19.

Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading.

Spatz JM, Ellman R, Cloutier AM, Louis L, van Vliet M, Suva LJ, Dwyer D, Stolina M, Ke HZ, Bouxsein ML.

J Bone Miner Res. 2013 Apr;28(4):865-74. doi: 10.1002/jbmr.1807.

20.

Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus.

Hamann C, Rauner M, Höhna Y, Bernhardt R, Mettelsiefen J, Goettsch C, Günther KP, Stolina M, Han CY, Asuncion FJ, Ominsky MS, Hofbauer LC.

J Bone Miner Res. 2013 Mar;28(3):627-38. doi: 10.1002/jbmr.1803.

21.

Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels.

Jastrzebski S, Kalinowski J, Stolina M, Mirza F, Torreggiani E, Kalajzic I, Won HY, Lee SK, Lorenzo J.

J Bone Miner Res. 2013 Mar;28(3):618-26. doi: 10.1002/jbmr.1773.

22.

Early response of bone marrow osteoprogenitors to skeletal unloading and sclerostin antibody.

Shahnazari M, Wronski T, Chu V, Williams A, Leeper A, Stolina M, Ke HZ, Halloran B.

Calcif Tissue Int. 2012 Jul;91(1):50-8. doi: 10.1007/s00223-012-9610-9. Epub 2012 May 27.

PMID:
22644321
23.

Local delivery of recombinant osteoprotegerin enhances postorthodontic tooth stability.

Hudson JB, Hatch N, Hayami T, Shin JM, Stolina M, Kostenuik PJ, Kapila S.

Calcif Tissue Int. 2012 Apr;90(4):330-42. doi: 10.1007/s00223-012-9579-4. Epub 2012 Mar 1.

PMID:
22382900
24.

A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease.

Hsu H, Khare SD, Lee F, Miner K, Hu YL, Stolina M, Hawkins N, Chen Q, Ho SY, Min H, Xiong F, Boone T, Zack DJ.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2):197-201. Epub 2012 Apr 13.

PMID:
22325420
25.

OPG-Fc treatment in growing pigs leads to rapid reductions in bone resorption markers, serum calcium, and bone formation markers.

Sipos W, Zysset P, Kostenuik P, Mayrhofer E, Bogdan C, Rauner M, Stolina M, Dwyer D, Sommerfeld-Stur I, Pendl G, Resch H, Dall'Ara E, Varga P, Pietschmann P.

Horm Metab Res. 2011 Dec;43(13):944-9. doi: 10.1055/s-0031-1295463. Epub 2011 Dec 7.

PMID:
22161252
26.

Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice.

Shahnazari M, Dwyer D, Chu V, Asuncion F, Stolina M, Ominsky M, Kostenuik P, Halloran B.

Bone. 2012 Mar;50(3):628-37. doi: 10.1016/j.bone.2011.11.010. Epub 2011 Nov 30.

PMID:
22154841
27.

Transient muscle paralysis degrades bone via rapid osteoclastogenesis.

Aliprantis AO, Stolina M, Kostenuik PJ, Poliachik SL, Warner SE, Bain SD, Gross TS.

FASEB J. 2012 Mar;26(3):1110-8. doi: 10.1096/fj.11-196642. Epub 2011 Nov 28.

28.

Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.

Tu X, Rhee Y, Condon KW, Bivi N, Allen MR, Dwyer D, Stolina M, Turner CH, Robling AG, Plotkin LI, Bellido T.

Bone. 2012 Jan;50(1):209-17. doi: 10.1016/j.bone.2011.10.025. Epub 2011 Oct 30.

29.

Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury.

Li X, Grisanti M, Fan W, Asuncion FJ, Tan HL, Dwyer D, Han CY, Yu L, Lee J, Lee E, Barrero M, Kurimoto P, Niu QT, Geng Z, Winters A, Horan T, Steavenson S, Jacobsen F, Chen Q, Haldankar R, Lavallee J, Tipton B, Daris M, Sheng J, Lu HS, Daris K, Deshpande R, Valente EG, Salimi-Moosavi H, Kostenuik PJ, Li J, Liu M, Li C, Lacey DL, Simonet WS, Ke HZ, Babij P, Stolina M, Ominsky MS, Richards WG.

J Bone Miner Res. 2011 Nov;26(11):2610-21. doi: 10.1002/jbmr.472.

30.

Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.

Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.

Endocrinology. 2011 Sep;152(9):3312-22. doi: 10.1210/en.2011-0252. Epub 2011 Jul 5.

PMID:
21733832
31.

Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones.

Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ.

J Bone Miner Res. 2011 May;26(5):1012-21. doi: 10.1002/jbmr.307.

32.

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.

Ominsky MS, Stouch B, Schroeder J, Pyrah I, Stolina M, Smith SY, Kostenuik PJ.

Bone. 2011 Aug;49(2):162-73. doi: 10.1016/j.bone.2011.04.001. Epub 2011 Apr 9.

PMID:
21497676
33.

Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy.

Bolon B, Stolina M, King C, Middleton S, Gasser J, Zack D, Feige U.

J Biomed Biotechnol. 2011;2011:569068. doi: 10.1155/2011/569068. Epub 2010 Dec 28. Review.

34.

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.

Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.

J Bone Miner Res. 2010 Dec;25(12):2647-56. doi: 10.1002/jbmr.182. Epub 2010 Jul 16. Erratum in: J Bone Miner Res. 2011 Feb;26(2):439.

35.

Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women.

Drake MT, Srinivasan B, Mödder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S.

J Clin Endocrinol Metab. 2010 Nov;95(11):5056-62. doi: 10.1210/jc.2010-0720. Epub 2010 Jul 14.

36.

Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.

Pierroz DD, Bonnet N, Baldock PA, Ominsky MS, Stolina M, Kostenuik PJ, Ferrari SL.

J Biol Chem. 2010 Sep 3;285(36):28164-73. doi: 10.1074/jbc.M110.101964. Epub 2010 Jun 17.

37.

RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.

Stolina M, Schett G, Dwyer D, Vonderfecht S, Middleton S, Duryea D, Pacheco E, Van G, Bolon B, Feige U, Zack D, Kostenuik P.

Arthritis Res Ther. 2009;11(6):R187. doi: 10.1186/ar2879. Epub 2009 Dec 11.

38.

RANKL-targeted therapy inhibits bone resorption in experimental Staphylococcus aureus-induced arthritis.

Verdrengh M, Bokarewa M, Ohlsson C, Stolina M, Tarkowski A.

Bone. 2010 Mar;46(3):752-8. doi: 10.1016/j.bone.2009.10.028. Epub 2009 Oct 30.

PMID:
19879986
39.

Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis.

Schett G, Stolina M, Dwyer D, Zack D, Uderhardt S, Krönke G, Kostenuik P, Feige U.

Arthritis Rheum. 2009 Sep;60(9):2644-54. doi: 10.1002/art.24767.

40.

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.

Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ.

Bone. 2009 Oct;45(4):669-76. doi: 10.1016/j.bone.2009.06.011. Epub 2009 Jun 17.

PMID:
19539794
41.

Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL.

Hofbauer LC, Zeitz U, Schoppet M, Skalicky M, Schüler C, Stolina M, Kostenuik PJ, Erben RG.

Arthritis Rheum. 2009 May;60(5):1427-37. doi: 10.1002/art.24445.

42.

One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength.

Ominsky MS, Stolina M, Li X, Corbin TJ, Asuncion FJ, Barrero M, Niu QT, Dwyer D, Adamu S, Warmington KS, Grisanti M, Tan HL, Ke HZ, Simonet WS, Kostenuik PJ.

J Bone Miner Res. 2009 Jul;24(7):1234-46. doi: 10.1359/jbmr.090215.

43.

The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis.

Stolina M, Bolon B, Dwyer D, Middleton S, Duryea D, Kostenuik PJ, Feige U, Zack DJ.

Biomarkers. 2008 Nov;13(7):692-712. doi: 10.1080/13547500802651911 .

PMID:
19096963
44.

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK.

J Bone Miner Res. 2009 Feb;24(2):182-95. doi: 10.1359/jbmr.081112.

45.

The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis.

Stolina M, Bolon B, Middleton S, Dwyer D, Brown H, Duryea D, Zhu L, Rohner A, Pretorius J, Kostenuik P, Feige U, Zack D.

J Clin Immunol. 2009 Mar;29(2):158-74. doi: 10.1007/s10875-008-9238-8. Epub 2008 Aug 26.

PMID:
18726678
46.

Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice.

Lloyd SA, Yuan YY, Kostenuik PJ, Ominsky MS, Lau AG, Morony S, Stolina M, Asuncion FJ, Bateman TA.

Calcif Tissue Int. 2008 May;82(5):361-72. doi: 10.1007/s00223-008-9133-6. Epub 2008 May 9.

PMID:
18465074
47.

RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.

Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ.

J Bone Miner Res. 2008 May;23(5):672-82. doi: 10.1359/jbmr.080109.

48.

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C.

J Bone Miner Res. 2008 Jun;23(6):860-9. doi: 10.1359/jbmr.080216.

49.

Oestrogen exhibits type II collagen protective effects and attenuates collagen-induced arthritis in rats.

Nielsen RH, Christiansen C, Stolina M, Karsdal MA.

Clin Exp Immunol. 2008 Apr;152(1):21-7. doi: 10.1111/j.1365-2249.2008.03594.x. Epub 2008 Jan 28.

50.

Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.

Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL.

Circulation. 2008 Jan 22;117(3):411-20. doi: 10.1161/CIRCULATIONAHA.107.707380. Epub 2008 Jan 2.

Supplemental Content

Loading ...
Support Center